Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives

2017 ◽  
Vol 24 (28) ◽  
Author(s):  
Lazaros I. Sakkas ◽  
Athanasios Mavropoulos ◽  
Dimitrios P. Bogdanos
Keyword(s):  
Mode Of Action ◽  
Clinical Applications ◽  
Future Perspectives ◽  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitors ◽  
Immune Mediated

Wirksamkeit des neuen Phosphodiesterase 4-Inhibitors Roflumilast bei Rauchern und Exrauchern mit COPD

Pneumologie ◽  
2012 ◽  
Vol 66 (S 01) ◽  
Author(s):  
A Kroker ◽  
J Eller ◽  
A Linnhof ◽  
H Rusch ◽  
H Worth ◽  
...  
Keyword(s):  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitors

Recent Advances in Computational Methods for Identifying Anticancer Peptides

2019 ◽  
Vol 20 (5) ◽  
pp. 481-487 ◽  
Author(s):  
Pengmian Feng ◽  
Zhenyi Wang
Keyword(s):  
Computational Methods ◽  
Clinical Applications ◽  
Future Perspectives ◽  
Small Peptides ◽  
Accurate Identification ◽  
Normal Cells ◽  
Anticancer Peptide ◽  
Anticancer Peptides ◽  
Computational Identification ◽  
Reliable Methods

Anticancer peptide (ACP) is a kind of small peptides that can kill cancer cells without damaging normal cells. In recent years, ACP has been pre-clinically used for cancer treatment. Therefore, accurate identification of ACPs will promote their clinical applications. In contrast to labor-intensive experimental techniques, a series of computational methods have been proposed for identifying ACPs. In this review, we briefly summarized the current progress in computational identification of ACPs. The challenges and future perspectives in developing reliable methods for identification of ACPs were also discussed. We anticipate that this review could provide novel insights into future researches on anticancer peptides.

CDP840. A prototype of a novel class of orally active anti-Inflammatory phosphodiesterase 4 inhibitors

2002 ◽  
Vol 12 (11) ◽  
pp. 1451-1456 ◽  
Author(s):  
R.P. Alexander ◽  
G.J. Warrellow ◽  
M.A.W. Eaton ◽  
E.C. Boyd ◽  
J.C. Head ◽  
...  
Keyword(s):  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitors ◽  
Anti Inflammatory ◽  
Orally Active

scholarly journals Anti-Inflammatory and Utero-Relaxant Effects in Human Myometrium of New Generation Phosphodiesterase 4 Inhibitors

2004 ◽  
Vol 70 (2) ◽  
pp. 458-464 ◽  
Author(s):  
Stéphanie Oger ◽  
Céline Méhats ◽  
Mary S. Barnette ◽  
Françoise Ferré ◽  
Dominique Cabrol ◽  
...  
Keyword(s):  
Human Myometrium ◽  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitors ◽  
Anti Inflammatory ◽  
New Generation

Phosphodiesterase 4 Inhibitor Roflumilast Improves the Bronchodilative Effect of Sevoflurane in Sensitized Airways

2014 ◽  
Vol 120 (5) ◽  
pp. 1152-1159 ◽  
Author(s):  
Jing Zhou ◽  
Sohshi Iwasaki ◽  
Michiaki Yamakage
Keyword(s):  
Smooth Muscle ◽  
Volatile Anesthetic ◽  
Cyclic Adenosine Monophosphate ◽  
Relaxation Effect ◽  
Adenosine Monophosphate ◽  
Bronchodilator Effect ◽  
Phosphodiesterase 4 ◽  
Phosphodiesterase 4 Inhibitors ◽  
Lung Resistance ◽  
Total Lung Resistance

Abstract Background: Although phosphodiesterase 4 inhibitors and the volatile anesthetic sevoflurane are known to have independent bronchodilator properties, the combined administration of these two agents may have the potential to exert an additive or synergistic bronchodilator effect. The authors tested this hypothesis and investigated the common site of this combined relaxation effect in a model of airway hyperresponsiveness with ovalbumin-sensitized guinea pigs. Methods: Ovalbumin-sensitized animals (n = 138) were randomized into six groups: sensitized, sevoflurane, rolipram1.0, roflumilast1.0, sevoflurane/rolipram1.0, and sevoflurane/roflumilast1.0. Total lung resistance in vivo, airway smooth muscle tension in vitro, and intracellular cyclic adenosine monophosphate levels were measured to evaluate the relaxation effect. Results: Among the six sensitized groups, total lung resistance was higher in the order of sensitized > sevoflurane > rolipram 1.0 > roflumilast1.0 > sevoflurane/rolipram1.0 > sevoflurane/roflumilast1.0, with an increase in acetylcholine concentration. Compared with the other five groups, the muscle tensions in the sevoflurane/roflumilast1.0 group were significantly lower at carbacholine doses of 10−7, 10−6, and 10−5 M; the cyclic adenosine monophosphate concentrations (means ± SD) in the sevoflurane/rolipram1.0 (1.61 ± 0.34) and sevoflurane/roflumilast1.0 (1.50 ± 0.20) groups were higher than that in the sensitized (0.52 ± 0.15) and sevoflurane (1.12 ± 0.32) groups. Conclusions: The combined use of phosphodiesterase 4 inhibitors with the volatile anesthetic sevoflurane had an additive bronchodilator effect in ovalbumin-sensitized guinea pigs. The concurrent increase in cyclic adenosine monophosphate levels in sensitized airway smooth muscle might be a mechanism of this combined relaxation effect.

Diphosphonates Mode of Action and Clinical Applications

1977 ◽  
pp. 279-289 ◽  
Author(s):  
H. Fleisch ◽  
D. Fast ◽  
R. Rizzoli ◽  
U. Trechsel ◽  
J.-P. Bonjour
Keyword(s):  
Mode Of Action ◽  
Clinical Applications
Sign in / Sign up

Export Citation Format

Share Document